450 related articles for article (PubMed ID: 23617323)
1. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
Qiao W; Zhao J; Xing Y; Wang C; Wang T
Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
3. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
Dickinson M; Hoyt R; Roberts AW; Grigg A; Seymour JF; Prince HM; Szer J; Ritchie D
Br J Haematol; 2010 Jul; 150(1):39-45. PubMed ID: 20507301
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.
Sauter CS; Matasar MJ; Meikle J; Schoder H; Ulaner GA; Migliacci JC; Hilden P; Devlin SM; Zelenetz AD; Moskowitz CH
Blood; 2015 Apr; 125(16):2579-81. PubMed ID: 25758829
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of 2-Deoxy-2-[
Dai N; Zhou Y; Deng S; Sang S; Wu Y
Contrast Media Mol Imaging; 2021; 2021():5510825. PubMed ID: 33958977
[TBL] [Abstract][Full Text] [Related]
7. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
Roland V; Bodet-Milin C; Moreau A; Gastinne T; Mahé B; Dubruille V; Maisonneuve H; Juge-Morineau N; Moreau P; Jardel H; Planche L; Mohty M; Moreau P; Harousseau JL; Kraeber-Bodéré F; Le Gouill S
Bone Marrow Transplant; 2011 Mar; 46(3):393-9. PubMed ID: 20577223
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
Svoboda J; Andreadis C; Elstrom R; Chong EA; Downs LH; Berkowitz A; Luger SM; Porter DL; Nasta S; Tsai D; Loren AW; Siegel DL; Glatstein E; Alavi A; Stadtmauer EA; Schuster SJ
Bone Marrow Transplant; 2006 Aug; 38(3):211-6. PubMed ID: 16770314
[TBL] [Abstract][Full Text] [Related]
10. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
11. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
Hoppe BS; Moskowitz CH; Zhang Z; Maragulia JC; Rice RD; Reiner AS; Hamlin PA; Zelenetz AD; Yahalom J
Bone Marrow Transplant; 2009 Jun; 43(12):941-8. PubMed ID: 19139730
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB
Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
15. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
16. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Apr; 48(4):551-6. PubMed ID: 22964592
[TBL] [Abstract][Full Text] [Related]
19. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Moskowitz CH; Matasar MJ; Zelenetz AD; Nimer SD; Gerecitano J; Hamlin P; Horwitz S; Moskowitz AJ; Noy A; Palomba L; Perales MA; Portlock C; Straus D; Maragulia JC; Schoder H; Yahalom J
Blood; 2012 Feb; 119(7):1665-70. PubMed ID: 22184409
[TBL] [Abstract][Full Text] [Related]
20. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
